Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine Trials

Overview

Journal J Immunol Methods

Publisher Elsevier

Specialties Allergy & Immunology
Pathology

Date 2014 May 3

PMID 24787274

Citations 21

Authors

Anna Sambor

Ambrosia Garcia

Mark Berrong

Joy Pickeral

Sara Brown

Wes Rountree

Ana Sanchez

Justin Pollara

Nicole Frahm

Sarah Keinonen

Gustavo H Kijak

Mario Roederer

Gail Levine

M Patricia DSouza

Maria Jaimes

Richard Koup

Thomas Denny

Josephine Cox

Guido Ferrari

Affiliations

Soon will be listed here.

Abstract

A large repository of cryopreserved peripheral blood mononuclear cells (PBMCs) samples was created to provide laboratories testing the specimens from human immunodeficiency virus-1 (HIV-1) vaccine clinical trials the material for assay development, optimization, and validation. One hundred thirty-one PBMC samples were collected using leukapheresis procedure between 2007 and 2013 by the Comprehensive T cell Vaccine Immune Monitoring Consortium core repository. The donors included 83 human immunodeficiency virus-1 (HIV-1) seronegative and 32 HIV-1 seropositive subjects. The samples were extensively characterized for the ability of T cell subsets to respond to recall viral antigens including cytomegalovirus, Epstein-Barr virus, influenza virus, and HIV-1 using Interferon-gamma (IFN-γ) enzyme linked immunospot (ELISpot) and IFN-γ/interleukin 2 (IL-2) intracellular cytokine staining (ICS) assays. A subset of samples was evaluated over time to determine the integrity of the cryopreserved samples in relation to recovery, viability, and functionality. The principal results of our study demonstrate that viable and functional cells were consistently recovered from the cryopreserved samples. Therefore, we determined that this repository of large size cryopreserved cellular samples constitutes a unique resource for laboratories that are involved in optimization and validation of assays to evaluate T, B, and NK cellular functions in the context of clinical trials.

Citing Articles

Preservation of functionality, immunophenotype, and recovery of HIV RNA from PBMCs cryopreserved for more than 20 years.

Dyer W, Suzuki K, Levert A, Starr M, Lloyd A, Zaunders J Front Immunol. 2024; 15:1382711.

PMID: 39221258 PMC: 11361978. DOI: 10.3389/fimmu.2024.1382711.

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.

Williams L, Shen X, Sawant S, Akapirat S, Dahora L, Tay M PLoS Pathog. 2023; 19(5):e1011359.

PMID: 37256916 PMC: 10284421. DOI: 10.1371/journal.ppat.1011359.

Validation of the performance and suitability of a new class of FBS optimized for use in single-cell functional assays.

Berrong M, Ferrari G, Porth C, Davis D, Denny T, Janetzki S J Immunol Methods. 2023; 515:113452.

PMID: 36858170 PMC: 11495192. DOI: 10.1016/j.jim.2023.113452.

Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.

Curtis 2nd A, Saha P, Dennis M, Berendam S, Ramasubramanian P, Cross K mSphere. 2022; 7(1):e0083921.

PMID: 35196125 PMC: 8865927. DOI: 10.1128/msphere.00839-21.

Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features.

Cheng H, Dowell K, Bailey-Kellogg C, Goods B, Love J, Ferrari G Retrovirology. 2021; 18(1):35.

PMID: 34717659 PMC: 8557579. DOI: 10.1186/s12977-021-00579-9.

References

Reimann K, Chernoff M, Wilkening C, Nickerson C, Landay A . Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology.... Clin Diagn Lab Immunol. 2000; 7(3):352-9. PMC: 95878. DOI: 10.1128/CDLI.7.3.352-359.2000. View

Hansen S, Sacha J, Hughes C, Ford J, Burwitz B, Scholz I . Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science. 2013; 340(6135):1237874. PMC: 3816976. DOI: 10.1126/science.1237874. View

Perfetto S, Chattopadhyay P, Lamoreaux L, Nguyen R, Ambrozak D, Koup R . Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods. 2006; 313(1-2):199-208. DOI: 10.1016/j.jim.2006.04.007. View

Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke M, Arlehamn C . Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013; 39(4):758-69. PMC: 3996844. DOI: 10.1016/j.immuni.2013.08.031. View

Gill D, Huang Y, Levine G, Sambor A, Carter D, Sato A . Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One. 2010; 5(12):e14330. PMC: 3001861. DOI: 10.1371/journal.pone.0014330. View

Haynes B, B Gilbert P, McElrath M, Zolla-Pazner S, Tomaras G, Alam S . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. PMC: 3371689. DOI: 10.1056/NEJMoa1113425. View

Perfetto S, Ambrozak D, Nguyen R, Chattopadhyay P, Roederer M . Quality assurance for polychromatic flow cytometry. Nat Protoc. 2007; 1(3):1522-30. DOI: 10.1038/nprot.2006.250. View

Weinberg A, Song L, Wilkening C, Fenton T, Hural J, Louzao R . Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J Immunol Methods. 2010; 363(1):42-50. PMC: 3068047. DOI: 10.1016/j.jim.2010.09.032. View

Plotkin S . Complex correlates of protection after vaccination. Clin Infect Dis. 2013; 56(10):1458-65. DOI: 10.1093/cid/cit048. View

10.

Ozaki D, Gao H, Todd C, Greene K, Montefiori D, Sarzotti-Kelsoe M . International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS One. 2012; 7(1):e30963. PMC: 3267749. DOI: 10.1371/journal.pone.0030963. View

11.

Horton H, Thomas E, Stucky J, Frank I, Moodie Z, Huang Y . Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007; 323(1):39-54. PMC: 2683732. DOI: 10.1016/j.jim.2007.03.002. View

12.

Cox J, Ferrari G, Kalams S, Lopaczynski W, Oden N, DSouza M . Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005; 21(1):68-81. DOI: 10.1089/aid.2005.21.68. View

13.

Bonsignori M, Alam S, Liao H, Verkoczy L, Tomaras G, Haynes B . HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol. 2012; 20(11):532-9. PMC: 3757512. DOI: 10.1016/j.tim.2012.08.011. View

14.

Weinberg A, Song L, Wilkening C, Sevin A, Blais B, Louzao R . Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol. 2009; 16(8):1176-86. PMC: 2725535. DOI: 10.1128/CVI.00342-08. View

15.

Lamoreaux L, Roederer M, Koup R . Intracellular cytokine optimization and standard operating procedure. Nat Protoc. 2007; 1(3):1507-16. DOI: 10.1038/nprot.2006.268. View

16.

Britten C, Janetzki S, Butterfield L, Ferrari G, Gouttefangeas C, Huber C . T cell assays and MIATA: the essential minimum for maximum impact. Immunity. 2012; 37(1):1-2. DOI: 10.1016/j.immuni.2012.07.010. View

17.

Alter G, Altfeld M . NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med. 2008; 265(1):29-42. PMC: 2842208. DOI: 10.1111/j.1365-2796.2008.02045.x. View

18.

Li F, Malhotra U, B Gilbert P, Hawkins N, Duerr A, McElrath J . Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine. 2006; 24(47-48):6893-904. DOI: 10.1016/j.vaccine.2006.06.009. View

19.

Plotkin S . Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47(3):401-9. DOI: 10.1086/589862. View

20.

Currier J, Kuta E, Turk E, Earhart L, Loomis-Price L, Janetzki S . A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002; 260(1-2):157-72. DOI: 10.1016/s0022-1759(01)00535-x. View